Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf027 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Nicholas S Teran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Cyclopropanes, Sulfides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Vancomycin ranks among the most utilized antimicrobial agents in the treatment of serious β-lactam–resistant gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in preclinical models with adjuvant montelukast. The purpose of the study was to ascertain if montelukast was associated with a reduction in the prevalence of vancomycin-associated AKI.
Methods
This retrospective cohort study examined adult patients who received intravenous vancomycin between January 2020 and January 2024. The RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease) were employed in identifying cases of AKI. Additionally, a preclinical vancomycin-associated nephrotoxicity model was established to provide insights into possible renal protective mechanisms.
Results
Patients receiving montelukast (n = 110) were compared with controls (n = 330), of which AKI was observed in 3 (2.7%) vs 35 (10.6%), respectively (P = .01). A multivariate logistic regression analysis revealed that weight (odds ratio [OR], 1.02; 95% CI, 1.006–1.03; P = .005) and intensive care unit admission (OR, 6.88; 95% CI, 2.96–18.8; P < .001) were independently associated with AKI, while montelukast (OR, 0.26; 95% CI, .06–.77; P = .03) and male gender were protective (OR, 0.41; 95% CI, .19–.85; P = .02). Our in vitro model also revealed that adjuvant montelukast can reduce injury to proximal tubule cells through activation of the p62/KEAP-1/HO-1 antioxidant pathway.
Conclusions
Our study suggests that montelukast during vancomycin therapy may be protective against AKI, which may reduce patient harm and hospitalization costs. Further studies are warranted to validate our findings prospectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston.
- Department of Pharmacy, Baylor St Luke's Medical Center.
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston.
- Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston.
- Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Texas Medical Center.
ORCID-Profile: Nicholas S Teran, Cole S Hudson, Kady Phe, Yang Zhang, Hua Chen, Vincent H Tam
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Teran, N. S., Hudson, C. S., Phe, K., Wang, Y., Zhang, Y., Chen, H., Nigo, M., & Tam, V. H. (2025). Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf027
Vancouver
Teran NS, Hudson CS, Phe K, Wang Y, Zhang Y, Chen H, et al. Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf027
BibTeX
@article{Teran2025,
author = {Teran, Nicholas S and Hudson, Cole S and Phe, Kady and Wang, Yunting and Zhang, Yang and Chen, Hua and Nigo, Masayuki and Tam, Vincent H},
title = {Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf027}
}
EUVIMED